Diabetic Foot Ulcer (DFU) Treatment Market By Ulcer Type (Neuro-ischemic Ulcers, Neuropathic Ulcers, and Ischemic Ulcers) Treatment (Wound Care Dressings, Biologics, Negative Pressure Wound Therapy Devices, Therapy Devices, Antibiotic Medication, Others), End-user (Hospitals & Clinics, Ambulatory Surgical Centre, and Others), and Region - Market Perspective, Market Intelligence, Comprehensive Analysis, Historical Data, and Forecast for 2023–2032

Market Perspective

The global Diabetic Foot Ulcer (DFU) Treatment Market size was worth around USD 6.6 billion in 2022 and is projected to reach around USD 10.9 billion by 2032 at a CAGR of 5.1% between 2023 and 2032.

The rise in the prevalence of chronic illnesses, particularly diabetes, caused by modern lifestyle habits and urbanization, is driving the growth of this market. Diabetes leads to decreased healing power in the body and an increased risk of complications, including diabetic foot ulcers, which occur when wounds on the feet rapidly decompose and produce infectious microorganisms.

With the global incidence of diabetic foot ulcers estimated at 9.1 to 26.1 million per year and 15-25% of diabetic patients expected to develop them, the number of cases is on the rise. The increasingly sedentary lifestyle and obesity also contribute to the development of diabetic foot ulcers. Effective DFU management requires a coordinated effort by multidisciplinary specialists and a holistic approach to address co-morbidities, in order to prevent foot amputations and reduce the risk of ulcer recurrence.

Key Insights

• Based on the ulcer type, the neuro-ischemic ulcers segment held the largest market share
• Based on treatment, the biologics segment generated the highest revenue
• By end-user, hospital segments are expected to dominate over the forecast period
• On the basis of region, North America accounted for the largest market share

Increasing Prevalence of Diabetic Foot Ulcer Augments the Market Growth

A diabetic foot ulcer is one of the most serious and devastating complications of diabetes and as diabetes became more common, its complications increased tremendously. The increased incidence is attributed to several factors such as age, sedentary lifestyle, and longer duration of diabetes. The prevalence of foot ulcers is growing among the large population of diabetic patients seeking for foot ulcer treatment.

The increasing awareness among the patient population about the availability of treatment and increasing healthcare costs, especially in developing countries, further boosts the market during the forecast period. According to the statistics, approximately 537 million adults (20-79 years) will have diabetes in 2021. The number of diabetics is expected to increase to 643 million by 2030 and 783 million by 2045. In addition to this, 3 in 4 adults are living with diabetes majorly in low- and middle-income countries and a significant number of the diabetic populations suffer from foot ulcers which accelerates the need for the diabetic foot ulcer treatment market. The increasing incidence of diabetes and the increasing incidence of diabetic foot ulcers is likely to have a positive impact on the global treatment of diabetic foot ulcers market.

The high cost of Advanced Wound Care Devices and Therapies Restricts the Market Growth

The prevalence of foot ulcers is growing globally, but the high cost of treatment is hindering the market's growth. Advanced wound care devices are expensive, and limited reimbursement in developing regions is one of the key hindrances. The cost of treating diabetic foot ulcers is substantial and disproportionately high compared to the severity of the condition. High-grade ulcers cost 8 times more to treat than low-grade ulcers.

Apart from this, patients with diabetic foot ulcers require frequent ER visits, hospitalization, and longer hospital stays, further adding to the cost. Aggressive therapies, like revascularization procedures and advanced wound care, are expensive but necessary for limb salvage. Despite the high cost, these procedures can reduce long-term costs, which may limit the market growth.

Technological Advancements in Treatment Options in Developed Countries to Drive Market

Diabetic foot ulcers are a major complication of diabetes and a leading cause of morbidity worldwide. The market for diabetic foot treatment is expected to grow with advancements in treatment options, such as biotechnological skin substitutes, extracellular matrix proteins, and therapeutic agents.

Recently, AI-based technologies have been developed for remote monitoring of diabetic foot ulcers using mobile apps, expected to greatly impact treatment. Future advancements in technology will lead to more accurate and scientific treatments, driving market expansion during the forecast period.

Recent Development

In January 2022: Alkem Laboratories Ltd. (Alkem) launched a unique patented technology for the treatment of Diabetic Foot Ulcer (DFU) in India. The 4D bioprinting technology helps treat deep, non-healing chronic wounds has a wide range of potential for the prevention of diabetic amputation.

Segmentation Analysis

Based on the ulcer type, the market is categorized into neuropathic ulcers, ischemic ulcers, and neuro-ischemic ulcers. The neuro-ischemic ulcers segment is expected to dominate over the forecast period. This can be attributed to the number of associated risks, such as infection, amputation, and death. Neuropathic ulcers account for approximately 35% of all ulcers, whereas neuro-ischemia affects approximately 50% of the diabetic population.

Based on treatment, the market is segmented into wound care dressings, biologics, negative pressure wound therapy devices, therapy devices, antibiotic medication, and others. The biologics segment is the most dominating owing to the cost-efficiency of these treatment procedures, less time taken to heal the wounds, and overall exudate management.

Based on end-user, the diabetic foot ulcer market is segmented into hospitals & clinics, ambulatory surgical centers, and others. The hospital & clinic is the most dominating segment owing to the greater footfall of patients and increasing accessibility of hospitals to all income level populations. The region's market expansion is influenced by the increased rate of treatment adoption, the availability of skilled personnel, and favorable reimbursement policies.

North America Accounted for the Largest Revenue Share Due to the Strong Presence of the Geriatric Population Suffering from Diabetic Foot Ulcers

In North America, the rise in sedentary lifestyles has led to an increase in diabetic foot ulcers. 1 in 7 adults in North America and the Caribbean region have diabetes, projected to reach 57 million by 2030 and 63 million by 2045. Diabetes is the leading cause of non-traumatic amputations in the US, with half of the 82,000 annual amputations occurring in individuals 65 and older.

The market for diabetic foot ulcer treatment in this region is driven by large market participants, rising healthcare expenditures, and improved reimbursement. This condition has a significant impact on patients and the healthcare system, and there is a need to study recent trends and the impact of comorbidities, providing opportunities for market vendors.

Asia Pacific is Growing at a Faster Rate Due to Expanding Applications across Several End-user Industries

The Asia-Pacific region is projected to see the fastest growth in the diabetic foot wound care market due to improvements in medical infrastructure, a growing diabetic population, and increasing cases of foot ulcers. Comorbidities like coronary artery disease and nephropathy are common among diabetics, leading to more serious injuries that require advanced wound care. Fueling market growth in the region are increasing research activities for new wound care products and the growing use of 3D printing in wound care.

In 2022, researchers at Queen's University Belfast developed a new, cost-effective bandage treatment for diabetic foot ulcers that improves patient outcomes and reduces DFU treatment costs and clinical burden. According to the International Diabetes Federation, the number of diabetics in Southeast Asia is expected to rise from nearly 90 million in 2021 to 152 million by 2045. Key factors driving the increase in DFU in the region include a large diabetic population, a high number of juvenile diabetics, and the high cost of treatment. Sixty percent of Type 2 diabetes patients live in China and India, with one in 11 adults having diabetes. This number is projected to reach 113 million by 2030 and 151 million by 2045. The market is expected to see the fastest growth during the forecast period due to high incidences of wounds and injuries, as well as the growing prevalence of diabetes.

Competitive Landscape

• 3M
• Alkem Labs
• Aurealis Therapeutics
• Braun SE
• Centaur Pharmaceuticals Pvt Ltd.
• Convatec Inc.
• Integra LifeSciences
• Kerecis
• Medline Industries, Inc.
• Mölnlycke Health Care AB

The global diabetic foot ulcer (DFU) treatment market is segmented as follows:

By Ulcer Type

• Neuro-ischemic Ulcers
• Neuropathic Ulcers
• Ischemic Ulcers

By Treatment

• Wound Care Dressings
• Biologics
• Negative Pressure Wound Therapy Devices
• Therapy Devices
• Antibiotic Medication
• Others

By End-user

• Hospitals & Clinics,
• Ambulatory Surgical Centre
• Others

By Region

• North America
  • The U.S.
  • Canada
  • Mexico
• Europe
  • France
  • The UK
  • Spain
  • Germany
  • Italy
  • Nordic countries
    • Denmark
    • Finland
    • Iceland
    • Sweden
    • Norway
  • Benelux Reunion
    • Belgium
    • The Netherlands
    • Luxembourg
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • New Zealand
  • Australia
  • South Korea
  • Southeast Asia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Rest of Southeast Asia
  • Rest of Asia Pacific
• The Middle East & Africa
  • Saudi Arabia
  • UAE
  • Egypt
  • Kuwait
  • South Africa
  • Rest of the Middle East & Africa
• Latin America
  • Brazil
  • Argentina
  • Rest of Latin America